Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.

MLA

Grau, Santiago, et al. “Comparison of the Design and Methodology of Phase 3 Clinical Trials of Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) and Dolutegravir-Based Dual Therapy (DTG) in HIV: A Systematic Review of the Literature.” Expert Review of Anti-Infective Therapy, vol. 21, no. 1, Jan. 2023, pp. 65–76. EBSCOhost, https://doi.org/10.1080/14787210.2023.2149490.

APA

Grau, S., Miró, J. M., Olalla, J., Alcalá, J. C., Castro, A., Rubio-Rodríguez, D., & Rubio-Terrés, C. (2023). Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature. Expert Review of Anti-Infective Therapy, 21(1), 65–76. https://doi.org/10.1080/14787210.2023.2149490

Chicago

Grau, Santiago, Jose Maria Miró, Julian Olalla, Juan C Alcalá, Antonio Castro, Dario Rubio-Rodríguez, and Carlos Rubio-Terrés. 2023. “Comparison of the Design and Methodology of Phase 3 Clinical Trials of Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) and Dolutegravir-Based Dual Therapy (DTG) in HIV: A Systematic Review of the Literature.” Expert Review of Anti-Infective Therapy 21 (1): 65–76. doi:10.1080/14787210.2023.2149490.